Business
Sen-Jam Pharmaceutical Appoints Global Life Sciences Leader Rute Fernandes as Executive Advisor to Accelerate Commercialization Pathways
Sen-Jam Pharmaceutical, a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics for inflammation-driven conditions, today announced the appointment of Rute Fernandes as Executive Advisor to support commercialization strategy, scenario planning, and launch readiness across the company's advancing pipeline.
About this update from Takeda Pharmaceutical Co. Ltd.
[{"type":"text","content":"HUNTINGTON, N.Y., Dec. 9, 2025 /PRNewswire/ -- Sen-Jam Pharmaceutical, a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics for inflammation-driven conditions, today announced the appointment of Rute Fernandes as Executive Advisor to support commercialization strategy, scenario planning, and launch readiness across the company's advancing pipeline.","length":383,"tagName":"p"},{"type":"text","content":"Fernandes, a global C-suite executive with more than 25 years of leadership experience across Big Pharma, biotech, and tech, has held CEO, Board, regional, and country-level roles at organizations including Novartis, Shire, and Takeda. She has led high-impact initiatives spanning drug development, rare disease strategy, commercial operations, global launches, digital transformation, and large-scale integrations—managing P&Ls exceeding $2 billion and delivering sustained double-digit growth.","length":499,"tagName":"p"},{"type":"text","content":"In her influential role at Sen-Jam, Fernandes will guide the company's commercialization planning and execution, including strategic scenario development, valuation frameworks, go-to-market models, partner exploration, and launch readiness for priority assets. Her work will support Sen-Jam's effort to maximize the value of its expanding anti-inflammatory platform, known for its unique multi-mechanism combination approach and accelerated 505(b)(2) regulatory pathway.","length":478,"tagName":"p"},{"type":"text","content":""Rute brings a rare combination of global insight, strategic clarity, and executional excellence," said Jim Iversen, CEO of Sen-Jam Pharmaceutical. "As we advance multiple assets toward late-stage development—including SJP-001 for hangover prevention and SJP-002C for metabolic inflammation—her experience will sharpen our commercial strategy and ensure each program is positioned for rapid and scalable impact."","length":432,"tagName":"p","attribs":{}},{"type":"text","content":"Fernandes will support Sen-Jam as the company continues to generate momentum across its pipeline, following recent commercial and clinical advances, including the increasingly valuable corporate venture/Chemistry, Manufacturing & Controls (CMC) partnership with KVK-Tech, a new patent filing in stimulant withdrawal expanding its addicti...